Search Results 641-650 of 18366 for alopecia

1. A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) - Mayo Clinic

   03) > Grade 1 from previous anti-cancer therapy (including radiotherapy), except alopecia. Any grade of neuropathy from any cause. Any prior oxaliplatin ...

2. A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer - Mayo Clinic

   o Subjects with type I diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders (such as vitiligo,psoriasis or alopecia) not ...

3. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   Any grade alopecia;; Peripheral sensory or motor neuropathy must have resolved to Grade ≤ 2. Measurable disease defined as at least one of the following ...

4. Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations - Mayo Clinic

   therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2 - Albumin levels < 2.5 g/dl - Any of the following because this study ...

5. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC) - Mayo Clinic

   Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion ...

6. Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer - Mayo Clinic

   * Residual toxicities from prior anti-cancer therapy that remain Grade \> 1, with the exception of alopecia and peripheral neuropathy. Toxicities related to ...

7. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

   Vitiligo, alopecia, hypothyroidism on stable doses of thyroid replacement therapy, psoriasis not requiring systemic therapy within the past 2 years are ...

8. A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Agree to refrain ...

9. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to Grade 1 or less (except for clinically non-significant toxicities such as alopecia). Age 18 ...

10. Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia - Mayo Clinic

    ... alopecia. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia. Unwilling or unable to participate in all required study evaluations and ...